Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder

ÇELİKEL ÇAM, Feryal; BENLİ, İsmail; DEMİR, Osman; ATEŞ, Ömer; TAYCAN ERDOĞAN, Serap; YILDIZ, Mesut

Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder

Mesut YILDIZ, (, Marmara University, Facultyof Medicine, Department of Psychiatry,Istanbul, Turkey)

Feryal ÇELİKEL ÇAM, (, Işık University, Department of Clinical Psychology, Institute of Social Sciences, Istanbul, Turkey)

Ömer ATEŞ, (Assoc. Prof., Gaziosmanpaşa University, Faculty of Medicine, Department of Medical Biology, Tokat, Turkey)

Serap TAYCAN ERDOĞAN, (Haydarpaşa Numune Training andResearch Hospital, Department of Psychiatry)

İsmail BENLİ, (, Gaziosmanpaşa University, Faculty ofMedicine, Department of Biochemistry,Tokat, Turkey)

Osman DEMİR (Gaziosmanpaşa University,Faculty of Medicine, Department ofBiostatistics, Tokat, Turkey)

Journal of Mood Disorders

4 1

Yıl: 2017 Cilt: 7 Sayı: 2 Sayfa Aralığı: 86 - 92 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder

Öz:

Objective: Oxidative and nitrosative stress pathways, along with immune-inflammatory response, might play animportant role in the pathogenic mechanisms underlying major depressive disorder and bipolar disorder. The aim of thepresent study is to investigate paraoxonase 1 polymorphisms and its correlations with disease parameters in patientswith major depressive disorder and bipolar disorder.Methods: PON1 L55M and Q192R single nucleotide polymorphisms were analyzed in a group consisted of 100 patientswith major depressive disorder, and 100 patients with bipolar disorder and 96 healthy controls. Polymorphisms wereanalyzed by using polymerase chain reaction.Results: There were no statistically significant differences between groups for the existence of PON1 genotypes.Additionally, there was no association between the PON1 genotypes and disease variables in both depressed and bipolarpatients.Conclusions: Evaluating the different stages of patients with mood disorders and examining the connection betweenPON1 polymorphisms and treatment outcomes will help us to clarify the relationship between PON1 and mood disorders.

Anahtar Kelime:

Konular: Psikiyatri

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siwek M, Sowa-Kucma M, Dudek D, Styczen K, Szewczyk B, Kotarska K, et al. Oxidative stress markers in affective disorders. Pharmacol Rep. 2013;65(6):1558-71. [CrossRef]
2. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev. 2014;45:46-62. [CrossRef]
3. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41(6):5239. [CrossRef]
4. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61(2):1424. [CrossRef]
5. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Shapkaitz I, et al. Antioxidant treatment of the glutathione deficiency in bipolar disorder with N-acetylcysteine: a double-blind randomised placebo controlled trial. Bipolar Disord. 2007:9:89.
6. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact. 1999;119-120:379-88. [CrossRef]
7. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richtera RJ, Jarvika GP, et al. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact. 2010;187(1-3):35561. [CrossRef]
8. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33(3):498-507. [CrossRef]
9. Ezzaher A, Mouhamed DH, Mechri A, Neffati F, Rejeb J, Omezzine A, et al. Association between bipolar I disorder and the L55M and Q192R polymorphisms of the paraoxonase 1 (PON1) gene. J Affect Disord. 2012;139(1):127. [CrossRef]
10. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52(3):598608.
11. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta. 2009;410(1-2):112. [CrossRef]
12. Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Timpson N, Ebrahim S, et al. The association of the paraoxonase (PON1) Q192R polymorphism with depression in older women: findings from the British Women's Heart and Health Study. J Epidemiol Community Health. 2007;61(1):857. [CrossRef]
13. Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, et al. Lowered plasma paraoxonase (PON) 1 activity is a trait marker of major depression and PON1 Q192R gene polymorphismsmoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord. 2014;159:23-30. [CrossRef]
14. Vargas Nunes SO, Pizzo de Castro MR, Moreira EG, Guembarovski RL, Barbosa DS, Vargas HO, et al. Association of paraoxonase (PON) 1 activity, glutathione S-transferase GST T1/M1 and STin. 2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. Neurosci Lett. 2015;585:132-7. [CrossRef]
15. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry. 2009;14(4):359-75. [CrossRef]
16. Rice NE, Bandinelli S, Corsi AM, Ferrucci L, Guralnik JM, Miller MA, Kumari M, Murray A, Frayling TM, Melzer D. The paraoxonase (PON1) Q192R polymorphism is not associated with poor health status or depression in the ELSA or INCHIANTI studies. Int J Epidemiol. 2009;38(5):13749. [CrossRef]
17. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Dirican M, et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1103-8. [CrossRef]
18. Kodydková J, Vávrová L, Zeman M, Jirák R, Macá?ek J, Sta?ková B, et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem.2009;42(13-14):1368-74. [CrossRef]
19. Barim AO, Aydin S, Colak R, Dag E, Deniz O, Sahin I. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem. 2009;42(1011):107681. [CrossRef]
20. Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(5):128490. [CrossRef]
21. Ezzaher A, Mouhamed DH, Mechri A, Araoud M, Neffati F, Douki W, et al. Lower paraoxonase 1 activity in Tunisian bipolar I patients. Ann Gen Psychiatry. 2010;9:36. [CrossRef]
22. American Psychiatric Association, 1994. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association.
23. Pocsai Z, Tóth Z, Paragh G, Szeles G, Adany R. Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real-time PCR technology. Clin Chim Acta. 2003; 332(1-2):316. [CrossRef]
24. IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.
25. Koda Y, Tachida H, Soejima M, Takenaka O, Kimura H. Population differences in DNA sequence variation and linkage disequilibrium at the PON1 gene. Ann Hum Genet. 2004;68(Pt2):1109. [CrossRef]
26. Rojas-Garcia AE, Solis-Heredia MJ, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol Appl Pharm. 2005;205(3):282-9. [CrossRef]
27. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40(9):1056-8. [CrossRef]
28. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32(11):2803-12. [CrossRef]
29. Kucukali CI, Aydin M, Ozkok E, Orhan N, Cakir U, Kilic G, et al. Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population. Psychiatr Genet. 2008;18(6):289-94. [CrossRef]
30. Paşca SP, Nemeş B, Vlase L, Gagyi CE, Dronca E, Miu AC, et al. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 2006;78(19):2244-8. [CrossRef]
31. Sullivan PF. Spurious genetic associations. Biol Psychiatry. 2007;61(10):1121-6. [CrossRef]

APA	YILDIZ M, ÇELİKEL ÇAM F, ATEŞ Ö, TAYCAN ERDOĞAN S, BENLİ İ, DEMİR O (2017). Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. , 86 - 92.
Chicago	YILDIZ Mesut,ÇELİKEL ÇAM Feryal,ATEŞ Ömer,TAYCAN ERDOĞAN Serap,BENLİ İsmail,DEMİR Osman Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. (2017): 86 - 92.
MLA	YILDIZ Mesut,ÇELİKEL ÇAM Feryal,ATEŞ Ömer,TAYCAN ERDOĞAN Serap,BENLİ İsmail,DEMİR Osman Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. , 2017, ss.86 - 92.
AMA	YILDIZ M,ÇELİKEL ÇAM F,ATEŞ Ö,TAYCAN ERDOĞAN S,BENLİ İ,DEMİR O Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. . 2017; 86 - 92.
Vancouver	YILDIZ M,ÇELİKEL ÇAM F,ATEŞ Ö,TAYCAN ERDOĞAN S,BENLİ İ,DEMİR O Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. . 2017; 86 - 92.
IEEE	YILDIZ M,ÇELİKEL ÇAM F,ATEŞ Ö,TAYCAN ERDOĞAN S,BENLİ İ,DEMİR O "Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder." , ss.86 - 92, 2017.
ISNAD	YILDIZ, Mesut vd. "Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder". (2017), 86-92.

APA	YILDIZ M, ÇELİKEL ÇAM F, ATEŞ Ö, TAYCAN ERDOĞAN S, BENLİ İ, DEMİR O (2017). Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. Journal of Mood Disorders, 7(2), 86 - 92.
Chicago	YILDIZ Mesut,ÇELİKEL ÇAM Feryal,ATEŞ Ömer,TAYCAN ERDOĞAN Serap,BENLİ İsmail,DEMİR Osman Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. Journal of Mood Disorders 7, no.2 (2017): 86 - 92.
MLA	YILDIZ Mesut,ÇELİKEL ÇAM Feryal,ATEŞ Ömer,TAYCAN ERDOĞAN Serap,BENLİ İsmail,DEMİR Osman Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. Journal of Mood Disorders, vol.7, no.2, 2017, ss.86 - 92.
AMA	YILDIZ M,ÇELİKEL ÇAM F,ATEŞ Ö,TAYCAN ERDOĞAN S,BENLİ İ,DEMİR O Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. Journal of Mood Disorders. 2017; 7(2): 86 - 92.
Vancouver	YILDIZ M,ÇELİKEL ÇAM F,ATEŞ Ö,TAYCAN ERDOĞAN S,BENLİ İ,DEMİR O Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder. Journal of Mood Disorders. 2017; 7(2): 86 - 92.
IEEE	YILDIZ M,ÇELİKEL ÇAM F,ATEŞ Ö,TAYCAN ERDOĞAN S,BENLİ İ,DEMİR O "Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder." Journal of Mood Disorders, 7, ss.86 - 92, 2017.
ISNAD	YILDIZ, Mesut vd. "Paraoxonase (PON1) L55M and Q192R Polymorphisms in Major Depressive Disorder and Bipolar Disorder". Journal of Mood Disorders 7/2 (2017), 86-92.